Abstract
In response to the raging COVID-19 pandemic, Bangladesh started its vaccine administration in early 2021; however, due to the rapid development and launch of the vaccines in the market, many people had concerns regarding the safety of these vaccines. The purpose of this study was to evaluate the side effects that were experienced by the Bangladeshi residents after receiving the first dose of the Oxford-AstraZeneca’s Covishield vaccine (ChAdOx1nCoV-19). The study was conducted using both online and printed questionnaires and the data were analysed using SPSS. The results included the responses of 474 vaccine recipients from March–April 2021. Pain at the site of injection, fever, myalgia, fatigue and headache were the most commonly reported symptoms, and the overall side effects were found to be significantly more prevalent in the younger population (p ≤ 0.05). These findings were consistent with the results indicated by the clinical trial of ChAdOx1nCoV-19. Logistic regression analysis further revealed that compared to people aged 70 years or above, the incidence of reported side effects was significantly higher in people aged 18–30 years (odds ratio (OR) = 8.56), 31–40 years, (OR = 5.05), 41–50 years (OR = 4.08), 51–60 years (OR = 3.77) and 61–70 years (OR = 3.67). In addition, a significantly higher percentage of female participants suffered from post-vaccination side effects compared to males (OR = 1.51). It was concluded that the Covishield vaccine was well-tolerated among people of different age groups. Nevertheless, further long-term follow-up study with a larger sample size is warranted to establish the long-term safety of the COVID-19 vaccine.
Highlights
This article is an open access articleThe world has been going through a global crisis since early 2020 due to the COVID-19 pandemic, which is caused by the newly discovered coronavirus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]
The purpose of this study was to assess the short-term side effects that were experienced by the recipients of the first dose of Oxford-AstraZeneca’s Covishield vaccine in Bangladesh
A cross-sectional study was conducted among Bangladeshi residents who were aged more than 18 years and who had received the first dose of the Covishield vaccine
Summary
The world has been going through a global crisis since early 2020 due to the COVID-19 pandemic, which is caused by the newly discovered coronavirus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The treatment of COVID patients with broad-spectrum antibiotics and antivirals has led to the recovery of patients to some extent, many of them have faced severe adverse effects. Many pharmaceutical companies and research centers have been racing to develop safe and effective vaccinations to tackle the pandemic [5]. According to recent WHO reports, more than 210 candidate vaccines are under development, out of which, at least 48 of them are already in human trials [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
